The history of Viagra presents a challenging picture for investors. While the initial introduction generated substantial profits, the end of its intellectual property protection opened the floodgates to off-brand competitors, dramatically eroding revenue. This poses a unique challenge for pharmaceutical companies relying on similar blockbuster prod

The story of Viagra, and its parent company copyright, presents a challenging case study for investors. Originally a blockbuster drug, generating billions in revenue , its exclusivity period created a flood of generic competition , significantly diminishing its market share . While certain pharmaceutical companies may try to capitalize on related t